---
type: "Topics"
locale: "en"
url: "https://longbridge.com/en/topics/100000000910406.md"
description: "$Eli Lilly(LLY.US)despite rivals posting encouraging clinical trial results, Eli Lily did not slide as many would expect. I believe it is their investments in R&D that will help keep it competitive in the market. Investments in their AI factory should pay off next year!"
datetime: "2026-09-23T02:47:48.000Z"
locales:
  - [en](https://longbridge.com/en/topics/100000000910406.md)
  - [zh-CN](https://longbridge.com/zh-CN/topics/100000000910406.md)
  - [zh-HK](https://longbridge.com/zh-HK/topics/100000000910406.md)
author: "[dhighstakes](https://longbridge.com/en/profiles/20757786.md)"
generator: "portal-rs"
---

# $Eli Lilly(LLY.US)despite rivals posting encouragi…


### Related Stocks

- [LLY.US](https://longbridge.com/en/quote/LLY.US.md)

## Comments (1)

- **Eunice · 2026-09-23T07:11:15.000Z · 👍 1**: for pharma the r and d payoff sits in the phase three readout calendar, and the bigger risk to the multiple is patent cliff timing rather than a rival's trial data.


---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**